查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
介入性心臟病学设备的全球市场：按类型 - 预测（至 2029 年）
市场调查报告书
商品编码
1622844

介入性心臟病学设备的全球市场：按类型 - 预测（至 2029 年）

Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 368 Pages | 订单完成后即时交付

价格

2024年，全球介入性心臟病设备市场规模达278亿美元，预计2029年将达到372.7亿美元，预测期内复合年增长率为6.0%。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 美元
部分 血管成形术支架、结构性心臟疾病设备、导管、血管成形术球囊、其他设备、最终用户、地区
目标区域 亚太地区、北美、拉丁美洲、中东/非洲

市场成长由多个关键因素推动。特别是全球心血管疾病（CVD）盛行率的不断上升、微创手术的进步以及对改善患者治疗效果的需求不断增长。随着心臟病、高血压和糖尿病盛行率的增加，对血管成形术、置入术和瓣膜置换术等有效治疗的需求也增加。药物释放型支架、生物可吸收支架和先进成像技术的开发等技术创新使手术变得更安全、更精确，从而促进了市场成长。

“根据血管成形术球囊类型，传统/常规球囊细分市场预计将以市场上最高的复合年增长率增长。”

传统血管成形术球囊（也称为 POBA）在某些临床场景中比药物释放型球囊 (DEB) 具有多种优势。首先，传统气球往往比 DEB 成本更低，这使得它们成为卫生系统和患者的好选择，特别是在卫生预算有限或报销政策可能无法完全覆盖 DEB 的地区。例如，在药物传递对治疗结果并不重要的紧急情况下，例如在治疗某些动脉闭塞时，POBA 可以提供足够的临床结果，而不会增加药物洗脱的复杂性或成本。

“血液动力学设备领域的栓塞预防设备领域预计将以市场上最高的复合年增长率增长。”

栓塞防护装置 (EPD) 是介入性心臟病学的一项重要进步，旨在捕获和清除血管手术期间可能脱落的碎片，从而最大限度地降低栓塞风险。这些装置在颈动脉支架置入术等干预措施中特别有用，因为脱落的颗粒可能会到达大脑并导致中风。透过捕获此类异物，EPD 显着降低了围手术期中风风险并提高了这些手术的安全性。

“其他设备领域的导管导引线领域预计将以市场上最高的复合年增长率增长。”

导管导引线在介入性心臟病学中至关重要，它提供精确性、灵活性和控制性，从而提高血管成形术和置入术等手术的安全性和有效性。这些细而柔韧的导线将导管引导到血管中，使临床医生能够导航复杂的血管结构并到达目标部位，同时最大限度地减少对周围组织的创伤。卓越的扭矩响应和可操作性使心臟科医生能够接近难以触及的病变，提高手术成功率，并减少开放性手术的需要。

本报告研究和分析了全球介入性心臟病学设备市场，提供了包括关键驱动因素和限制因素、竞争格局和未来趋势等资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 介入性心臟病学设备市场概述
  • 亚太地区介入性心臟病学设备市场：依最终用户分类
  • 介入性心臟病学设备市场：地理成长机会
  • 区域构成：介入性心臟病学设备市场（2022-2029）

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 产业趋势
    • 药物释放型技术
    • 微创手术的重要性日益增加
  • 供应链分析
  • 价值链分析
  • 技术分析
    • 主要技术
    • 邻近技术
    • 互补技术
  • 波特五力分析
  • 监管环境
    • 监管分析
    • 监管机构、政府机构和其他组织
  • 价格分析
    • 主要企业平均销售价格：依产品类型划分（2023年）
    • 以产品类型分類的介入性心臟病设备平均售价（2023年）
    • 平均售价：按地区
  • 生态系分析
  • 专利分析
    • 介入性心臟病学设备相关专利出版品的趋势
    • 讨论：司法管辖区和热门申请人分析
  • 贸易分析
    • 介入性心臟病学设备及耗材贸易分析
    • 海关编码
  • 重大会议和活动（2024-2025）
  • 主要相关利益者和采购标准
  • 未满足的需求/最终用户的期望
  • 人工智慧/产生人工智慧对介入性心臟病学设备市场的影响
  • 案例研究分析
  • 影响客户业务的趋势/干扰
  • 心臟病介入设备相关市场
  • 投资金筹措场景

第六章血管成形术支架市场：依类型

  • 介绍
    • 药物释放型支架
    • 裸金属支架
    • 生物可吸收支架

第七章结构性心臟疾病设备市场：依类型

  • 介绍
    • 主动脉瓣治疗设备
    • 其他处理设备

第八章导管市场：依类型

  • 介绍
    • 血管造影术导管
    • 引导管
    • IVUS/OCT 导管

第九章血管成形术球囊市场：依类型

  • 介绍
    • 旧/普通气球
    • 药物释放型球囊
    • 切割/球囊导管

第10章斑块去除设备市场：依类型

  • 介绍
    • 血栓除去装置
    • 斑块切除装置

第十一章血流调节装置市场：依类型

  • 介绍
    • 栓塞防护装置
    • 慢性全闭塞装置

第十二章其他介入性心臟病学设备市场：按类型

  • 介绍
    • 导管导引线
    • 血管闭合装置
    • 导引鞘
    • 球囊膨胀装置
    • 止血心臟瓣膜

第 13 章：介入性心臟病学设备市场：依最终用户分类

  • 介绍
  • 医院
  • 门诊手术中心
  • 其他最终用户

第 14 章：介入性心臟病学设备市场：按地区

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东/非洲
    • 中东和非洲宏观经济前景
    • 海湾合作委员会国家
    • 其他中东/非洲

第十五章竞争格局

  • 概述
  • 主要参与企业的策略/优势
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业（2023年）
  • 企业足迹
  • 企业评估矩阵：Start-Ups/中小企业（2023）
  • 公司评价及财务指标
  • 品牌/产品比较分析
  • 主要企业研发评价
  • 竞争场景

第十六章 公司简介

  • 主要企业
    • BOSTON SCIENTIFIC CORPORATION
    • MEDTRONIC
    • ABBOTT
    • KONINKLIJKE PHILIPS NV
    • TERUMO CORPORATION
    • EDWARDS LIFESCIENCES CORPORATION
    • B. BRAUN SE
    • INTEGER HOLDINGS CORPORATION
    • TELEFLEX INCORPORATED
    • PENUMBRA, INC.
    • COOK
    • CORDIS
    • IVASCULAR SLU
    • BIOSENSORS INTERNATIONAL GROUP, LTD.
    • BIOTRONIK SE & CO. KG
  • 其他公司
    • AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL)
    • ENDOCOR GMBH & CO. KG
    • INSITU TECHNOLOGIES, INC.
    • MERIL LIFE SCIENCES PVT. LTD
    • ALVIMEDICA
    • CARDIONOVUM GMBH
    • MEDINOL
    • WELLINQ
    • BALTON SP.
    • TRANSLUMINA

第十七章附录

Product Code: MD 3456

The global interventional cardiology devices market is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Angioplasty Stents, Structural Heart Devices, Catheters, Angioplasty Balloons, Other Devices, End user and Region
Regions coveredAsia Pacific, North America, Europe, Latin America, and the Middle East and Africa.

The growth of the interventional cardiology devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes. As rates of heart disease, hypertension, and diabetes rise, the need for effective treatments such as angioplasty, stenting, and valve replacements also increases. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market's growth.

"Based on the angioplasty balloons type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market."

Traditional angioplasty balloons, also known as plain old balloon angioplasty (POBA), offer several advantages over drug-eluting balloons (DEBs) in certain clinical scenarios. First, traditional balloons tend to be less costly than DEBs, making them a more accessible option for healthcare systems and patients, especially in regions with limited healthcare budgets or where reimbursement policies may not fully cover DEB, also POBA also has a simpler mechanism-it dilates narrowed blood vessels by compressing plaque against the vessel walls without releasing drugs, which can be beneficial in cases where the risks associated with drug delivery aren't justified. For example, in acute settings like treating certain types of arterial blockages where drug-delivery isn't critical to outcomes, POBA may provide sufficient clinical results without the added complexity or cost of drug elution.

"The embolic protection devices segment in hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."

Embolic protection devices (EPDs) are a vital advancement in interventional cardiology, designed to capture and remove debris that may dislodge during vascular procedures, thereby minimizing the risk of embolization. These devices are particularly beneficial during interventions like carotid artery stenting, where dislodged particles could travel to the brain and cause strokes. By capturing such debris, EPDs significantly reduce periprocedural stroke risks and improve the safety profile of these interventions.

"The guidewires segment in other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."

Guidewires are essential in interventional cardiology, offering precision, flexibility, and control that enhance the safety and effectiveness of procedures like angioplasty and stent placement. These thin, flexible wires guide catheters through blood vessels, allowing clinicians to navigate complex vascular structures and reach targeted areas with minimal trauma to surrounding tissues. Their superior torque response and maneuverability help cardiologists access difficult-to-reach lesions, improving procedural success rates and reducing the need for open surgery.

"Based on the end user, hospitals segment is expected to grow by the highest CAGR in the interventional cardiology devices market.

Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are carried out in hospitals because they boast special facilities and the sophisticated imaging technologies that would treat a patient with maximum quality. They are well equipped both for simple and complicated processes with a good staff; besides, they are where they can be managed whenever a complication arises. These settings enable cardiologists to take the latest tool systems into practice, including drug-eluting stents, rotational atherectomy and intravascular ultrasound, to ensure utmost precision and safety for patients.

"Asia Pacific to grow with the highest CAGR in the interventional cardiology devices market during the forecast period."

The Asia-Pacific region is also expected to experience maximum growth in the interventional cardiology devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the interventional cardiology devices market:

  • By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
  • By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
  • By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Key players in the interventional cardiology devices market

Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).

Research Coverage:

The report analyzes the interventional cardiology devices market and aims at estimating the market size and future growth potential of this market based on various segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user. The report also includes a product portfolio matrix of various interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional cardiology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

  • Of Analysis of key drivers (growing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, increased prevalence of diabetes & growing product launches by leading players in developing countries), restraints (availability of alternative treatments & recall of products by industry participants to limit the uptake of interventional cardiology equipment), opportunities (high growth potential in emerging markets & growing coronary stent demand in developing countries) and challenges (stringent regulatory requirements delaying the approval of cardiac devices).
  • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market
  • Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user.
  • Market Diversification: Exhaustive information about new product and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global interventional cardiology devices market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 MARKET STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 INTRODUCTION
    • 2.1.1 SECONDARY RESEARCH
    • 2.1.2 KEY DATA FROM SECONDARY SOURCES
      • 2.1.2.1 Primary data
    • 2.1.3 KEY DATA FROM PRIMARY SOURCES
      • 2.1.3.1 Insights from primary experts
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 DATA TRIANGULATION APPROACH
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER
  • 4.3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022-2029)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing prevalence of cardiovascular diseases
      • 5.2.1.2 Rising technological investments in interventional cardiology procedures
      • 5.2.1.3 Increasing prevalence of diabetes
      • 5.2.1.4 Favorable regulatory support
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Availability of alternative treatments
      • 5.2.2.2 Product recalls
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential in emerging markets
      • 5.2.3.2 Increasing demand for coronary stents
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory requirements for product approvals
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 DRUG-ELUTING TECHNOLOGIES
    • 5.3.2 INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 TECHNOLOGY ANALYSIS
    • 5.6.1 KEY TECHNOLOGIES
      • 5.6.1.1 TAVR technology
    • 5.6.2 ADJACENT TECHNOLOGIES
    • 5.6.3 COMPLEMENTARY TECHNOLOGIES
      • 5.6.3.1 Integration of real-time monitoring into wearable technologies
      • 5.6.3.2 Precise cardiovascular interventions through artificial intelligence
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF SUPPLIERS
    • 5.7.4 BARGAINING POWER OF BUYERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 REGULATORY LANDSCAPE
    • 5.8.1 REGULATORY ANALYSIS
      • 5.8.1.1 North America
        • 5.8.1.1.1 US
      • 5.8.1.2 Europe
    • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PRICING ANALYSIS
    • 5.9.1 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023
    • 5.9.2 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023
    • 5.9.3 INDICATIVE AVERAGE SELLING PRICE, BY REGION
  • 5.10 ECOSYSTEM ANALYSIS
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES
    • 5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.12 TRADE ANALYSIS
    • 5.12.1 TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES
    • 5.12.2 HS CODES
  • 5.13 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.16 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
  • 5.17 CASE STUDY ANALYSIS
    • 5.17.1 CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS
    • 5.17.2 CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS
    • 5.17.3 CASE STUDY 3: ABOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.19 ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES
  • 5.20 INVESTMENT & FUNDING SCENARIO

6 ANGIOPLASTY STENTS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • 6.1.1 DRUG-ELUTING STENTS
      • 6.1.1.1 Drug-eluting stents to hold largest share of angioplasty stents market
    • 6.1.2 BARE-METAL STENTS
      • 6.1.2.1 Increasing use of drug-eluting stents to limit growth of bare-metal stents market
    • 6.1.3 BIOABSORBABLE STENTS
      • 6.1.3.1 Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand

7 STRUCTURAL HEART DEVICES MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • 7.1.1 AORTIC VALVE THERAPY DEVICES
      • 7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth
    • 7.1.2 OTHER THERAPY DEVICES

8 CATHETERS MARKET, BY TYPE

  • 8.1 INTRODUCTION
    • 8.1.1 ANGIOGRAPHY CATHETERS
      • 8.1.1.1 Rising cases of artery disease and heart attacks to propel market
    • 8.1.2 GUIDING CATHETERS
      • 8.1.2.1 Increasing number of angiography procedures to drive the market
    • 8.1.3 IVUS/OCT CATHETERS
      • 8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth

9 ANGIOPLASTY BALLOONS MARKET, BY TYPE

  • 9.1 INTRODUCTION
    • 9.1.1 OLD/NORMAL BALLOONS
      • 9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth
    • 9.1.2 DRUG-ELUTING BALLOONS
      • 9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period
    • 9.1.3 CUTTING/SCORING BALLOONS
      • 9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth

10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE

  • 10.1 INTRODUCTION
    • 10.1.1 THROMBECTOMY DEVICES
      • 10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market
    • 10.1.2 ATHERECTOMY DEVICES
      • 10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth

11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE

  • 11.1 INTRODUCTION
    • 11.1.1 EMBOLIC PROTECTION DEVICES
      • 11.1.1.1 Adoption of filter & occlusion-based devices to propel market
    • 11.1.2 CHRONIC TOTAL OCCLUSION DEVICES
      • 11.1.2.1 Uptake in treatment of total occlusions to drive market

12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE

  • 12.1 INTRODUCTION
    • 12.1.1 GUIDEWIRES
      • 12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market
    • 12.1.2 VASCULAR CLOSURE DEVICES
      • 12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake
    • 12.1.3 INTRODUCER SHEATHS
      • 12.1.3.1 Ability to provide secure access to blood vessels to support market growth
    • 12.1.4 BALLOON INFLATION DEVICES
      • 12.1.4.1 Increasing incidence of peripheral artery disease to drive market
    • 12.1.5 HEMOSTASIS HEART VALVES
      • 12.1.5.1 Growing focus on precision medicine

13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 HOSPITALS
    • 13.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET
  • 13.3 AMBULATORY SURGERY CENTERS
    • 13.3.1 LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET
  • 13.4 OTHER END USERS

14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 14.2.2 US
      • 14.2.2.1 Availability of reimbursements for cardiology procedures to drive market
    • 14.2.3 CANADA
      • 14.2.3.1 Rising prevalence of chronic diseases to drive market
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 14.3.2 GERMANY
      • 14.3.2.1 Growing hub for advanced technology product distributors to drive market
    • 14.3.3 FRANCE
      • 14.3.3.1 Favorable government initiatives in France to support market growth
    • 14.3.4 UK
      • 14.3.4.1 Growing focus on personalized medicine to fuel uptake
    • 14.3.5 ITALY
      • 14.3.5.1 Increasing cases of obesity and CVD to support market growth
    • 14.3.6 SPAIN
      • 14.3.6.1 Increasing prevalence of age-related CVD conditions to drive market
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 14.4.2 CHINA
      • 14.4.2.1 High tobacco consumption and increasing cases of CVD to fuel uptake
    • 14.4.3 JAPAN
      • 14.4.3.1 Increasing demand for stents and catheters to support market growth
    • 14.4.4 INDIA
      • 14.4.4.1 Improvements in angioplasty devices to fuel uptake
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Increasing cases of lifestyle disorders to support market growth
    • 14.4.6 SOUTH KOREA
      • 14.4.6.1 Growth in pharmaceutical sectors to propel market
    • 14.4.7 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 14.5.2 BRAZIL
      • 14.5.2.1 Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market
    • 14.5.3 MEXICO
      • 14.5.3.1 Increasing cases of diabetes to fuel market
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
    • 14.6.2 GCC COUNTRIES
    • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
  • 15.3 REVENUE ANALYSIS
  • 15.4 MARKET SHARE ANALYSIS
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
  • 15.6 COMPANY FOOTPRINT
    • 15.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 15.6.1.1 Company footprint
      • 15.6.1.2 Region footprint
      • 15.6.1.3 Product footprint
      • 15.6.1.4 Angioplasty stents footprint
      • 15.6.1.5 Structural heart devices footprint
      • 15.6.1.6 Catheters footprint
      • 15.6.1.7 Angioplasty balloons footprint
      • 15.6.1.8 Plaque modification devices footprint
      • 15.6.1.9 Hemodynamic flow alteration devices footprint
      • 15.6.1.10 Other interventional cardiology devices footprint
      • 15.6.1.11 End-user footprint
  • 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 15.7.1 PROGRESSIVE COMPANIES
    • 15.7.2 RESPONSIVE COMPANIES
    • 15.7.3 DYNAMIC COMPANIES
    • 15.7.4 STARTING BLOCKS
    • 15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 15.8 COMPANY VALUATION & FINANCIAL METRICS
    • 15.8.1 FINANCIAL METRICS
    • 15.8.2 COMPANY VALUATION
  • 15.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 15.10 R&D ASSESSMENT OF KEY PLAYERS
  • 15.11 COMPETITIVE SCENARIO
    • 15.11.1 PRODUCT LAUNCHES & APPROVALS
    • 15.11.2 DEALS
    • 15.11.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 BOSTON SCIENTIFIC CORPORATION
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches & approvals
        • 16.1.1.3.2 Deals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 MEDTRONIC
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches & approvals
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 ABBOTT
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches & approvals
        • 16.1.3.3.2 Deals
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 KONINKLIJKE PHILIPS N.V.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Deals
    • 16.1.5 TERUMO CORPORATION
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches
        • 16.1.5.3.2 Expansions
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Key strengths
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses & competitive threats
    • 16.1.6 EDWARDS LIFESCIENCES CORPORATION
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product launches & approvals
        • 16.1.6.3.2 Deals
    • 16.1.7 B. BRAUN SE
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Product launches & approvals
        • 16.1.7.3.2 Deals
    • 16.1.8 INTEGER HOLDINGS CORPORATION
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
        • 16.1.8.3.2 Expansions
    • 16.1.9 TELEFLEX INCORPORATED
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product approvals
    • 16.1.10 PENUMBRA, INC.
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches & approvals
    • 16.1.11 COOK
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Deals
    • 16.1.12 CORDIS
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Product launches & approvals
        • 16.1.12.3.2 Deals
    • 16.1.13 IVASCULAR S.L.U.
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products offered
    • 16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD.
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Product launches
    • 16.1.15 BIOTRONIK SE & CO. KG
      • 16.1.15.1 Business overview
      • 16.1.15.2 Products offered
      • 16.1.15.3 Recent developments
        • 16.1.15.3.1 Product launches
  • 16.2 OTHER PLAYERS
    • 16.2.1 AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL)
    • 16.2.2 ENDOCOR GMBH & CO. KG
    • 16.2.3 INSITU TECHNOLOGIES, INC.
    • 16.2.4 MERIL LIFE SCIENCES PVT. LTD
    • 16.2.5 ALVIMEDICA
    • 16.2.6 CARDIONOVUM GMBH
    • 16.2.7 MEDINOL
    • 16.2.8 WELLINQ
    • 16.2.9 BALTON SP.
    • 16.2.10 TRANSLUMINA

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 INCLUSIONS & EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
  • TABLE 3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: STUDY ASSUMPTIONS
  • TABLE 4 RISK ASSESSMENT ANALYSIS: INTERVENTIONAL CARDIOLOGY DEVICES MARKET
  • TABLE 5 GLOBAL ANNUAL CARDIAC SURGICAL VOLUMES PER 100,000 POPULATION (2023)
  • TABLE 6 DIABETIC POPULATION, BY REGION, 2019 VS. 2030
  • TABLE 7 KEY COMPANIES INVOLVED IN PROVIDING DRUG-ELUTING TECHNOLOGIES
  • TABLE 8 BENEFITS OF TAVR OVER SAVR: PATIENT'S PERSPECTIVE
  • TABLE 9 COMPANIES PROVIDING FFR TECHNOLOGIES
  • TABLE 10 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY TYPE
  • TABLE 17 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023
  • TABLE 18 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ROLE IN ECOSYSTEM
  • TABLE 19 LIST OF PATENTS/PATENT APPLICATIONS IN THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2021-2023
  • TABLE 20 IMPORT DATA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY (2023)
  • TABLE 21 EXPORT DATA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY (2023)
  • TABLE 22 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS
  • TABLE 24 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 25 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 26 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: IMPACT OF GEN AI
  • TABLE 27 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 28 ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 29 ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 DRUG-ELUTING ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 DRUG-ELUTING ANGIOPLASTY STENTS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 32 BARE-METAL ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 BARE-METAL ANGIOPLASTY STENTS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 34 BIOABSORBABLE ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 36 STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 AORTIC VALVE THERAPY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 AORTIC VALVE THERAPY DEVICES MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 39 OTHER THERAPY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 OTHER THERAPY DEVICES MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 41 CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 42 CATHETERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 ANGIOGRAPHY CATHETERS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 45 GUIDING CATHETERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 GUIDING CATHETERS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 47 IVUS/OCT CATHETERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 IVUS/OCT CATHETERS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 49 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 50 ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 OLD/NORMAL ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 DRUG-ELUTING ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 DRUG-ELUTING ANGIOPLASTY BALLOONS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 54 CUTTING/SCORING ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 56 PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 PROCEDURE DATA FOR PLAQUE MODIFICATION DEVICES, BY REGION, 2023 (MILLION)
  • TABLE 58 THROMBECTOMY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 ATHERECTOMY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 61 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 OTHER DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 65 OTHER DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 GUIDEWIRES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 INTRODUCER SHEATHS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 BALLOON INFLATION DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 HEMOSTASIS HEART VALVES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 72 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 86 US: MACROECONOMIC INDICATORS
  • TABLE 87 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 88 US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 89 US: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 US: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 91 US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 92 US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 93 US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 94 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 95 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 96 CANADA: MACROECONOMIC INDICATORS
  • TABLE 97 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 98 CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 CANADA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 100 CANADA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 101 CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 103 CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 CANADA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 105 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 106 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 109 EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 113 EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 114 EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 115 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 116 GERMANY: MACROECONOMIC INDICATORS
  • TABLE 117 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 118 GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 GERMANY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 GERMANY: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 121 GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 122 GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 123 GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 124 GERMANY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 126 FRANCE: MACROECONOMIC INDICATORS
  • TABLE 127 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 FRANCE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 130 FRANCE: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 133 FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 FRANCE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 136 UK: MACROECONOMIC INDICATORS
  • TABLE 137 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 138 UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 139 UK: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 140 UK: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 143 UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 UK: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 146 ITALY: MACROECONOMIC INDICATORS
  • TABLE 147 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 148 ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 ITALY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 150 ITALY: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 151 ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 152 ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 153 ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 ITALY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 156 SPAIN: MACROECONOMIC INDICATORS
  • TABLE 157 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 SPAIN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 160 SPAIN: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 SPAIN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 166 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 167 REST OF EUROPE; ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 168 REST OF EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 169 REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 170 REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 REST OF EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 185 CHINA: MACROECONOMIC INDICATORS
  • TABLE 186 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 CHINA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 CHINA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 190 CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 191 CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 192 CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 CHINA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 194 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 195 JAPAN: MACROECONOMIC INDICATORS
  • TABLE 196 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 JAPAN: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 199 JAPAN CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 203 JAPAN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 205 INDIA: MACROECONOMIC INDICATORS
  • TABLE 206 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 207 INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 208 INDIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 209 INDIA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 212 INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 INDIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 215 AUSTRALIA: MACROECONOMIC INDICATORS
  • TABLE 216 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 AUSTRALIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 219 AUSTRALIA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 220 AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 221 AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 222 AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 AUSTRALIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 224 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 225 SOUTH KOREA: MACROECONOMIC INDICATORS
  • TABLE 226 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 227 SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 228 SOUTH KOREA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 229 SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 230 SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 233 SOUTH KOREA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 234 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 237 REST OF ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 245 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 246 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 247 LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 248 LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 249 LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 254 BRAZIL: MACROECONOMIC INDICATORS
  • TABLE 255 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 256 BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 BRAZIL: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 BRAZIL: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 261 BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 262 BRAZIL: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 264 MEXICO: MACROECONOMIC INDICATORS
  • TABLE 265 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 MEXICO: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 MEXICO: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 269 MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 271 MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 MEXICO: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 REST OF LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 279 REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 REST OF LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 287 MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 289 MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 291 MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 292 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 293 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 295 GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 296 GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 298 GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 299 GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 301 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 302 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 REST OF MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 307 REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 REST OF MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 310 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 311 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 312 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEGREE OF COMPETITION
  • TABLE 313 REGION FOOTPRINT
  • TABLE 314 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT FOOTPRINT
  • TABLE 315 ANGIOPLASTY STENTS FOOTPRINT
  • TABLE 316 STRUCTURAL HEART DEVICES FOOTPRINT
  • TABLE 317 CATHETERS FOOTPRINT
  • TABLE 318 ANGIOPLASTY BALLOONS FOOTPRINT
  • TABLE 319 PLAQUE MODIFICATION DEVICES FOOTPRINT
  • TABLE 320 HEMODYNAMIC FLOW ALTERATION DEVICES FOOTPRINT
  • TABLE 321 OTHER INTERVENTIONAL CARDIOLOGY DEVICES FOOTPRINT
  • TABLE 322 END-USER FOOTPRINT
  • TABLE 323 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 324 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 325 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 326 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEALS, JANUARY 2021- OCTOBER 2024
  • TABLE 327 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 328 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 329 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 330 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 331 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 332 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 333 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 334 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 335 MEDTRONIC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 336 ABBOTT: COMPANY OVERVIEW
  • TABLE 337 ABBOTT: PRODUCTS OFFERED
  • TABLE 338 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 339 ABBOTT: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 340 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 341 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 342 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 343 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 344 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 345 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 346 TERUMO CORPORATION.: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 347 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 348 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED
  • TABLE 349 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 350 EDWARDS LIFESCIENCES CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 351 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 352 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 353 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- OCTOBER 2024
  • TABLE 354 B. BRAUN SE: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 355 INTEGER HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 356 INTEGER HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 357 INTEGER HOLDINGS CORPORATION.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 358 INTEGER HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021- OCTOBER 2024
  • TABLE 359 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 360 TELEFLEX INCORPORATED: PRODUCTS OFFERED
  • TABLE 361 TELEFLEX INCORPORATED: PRODUCT APPROVALS, JANUARY 2021- OCTOBER 2024
  • TABLE 362 PENUMBRA, INC.: COMPANY OVERVIEW
  • TABLE 363 PENUMBRA, INC: PRODUCTS OFFERED
  • TABLE 364 PENUMBRA, INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- OCTOBER 2024
  • TABLE 365 COOK: COMPANY OVERVIEW
  • TABLE 366 COOK: PRODUCTS OFFERED
  • TABLE 367 COOK: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 368 CORDIS: COMPANY OVERVIEW
  • TABLE 369 CORDIS.: PRODUCTS OFFERED
  • TABLE 370 CORDIS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 371 CORDIS: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 372 IVASCULAR S.L.U.: COMPANY OVERVIEW
  • TABLE 373 IVASCULAR S.L.U: PRODUCTS OFFERED
  • TABLE 374 BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW
  • TABLE 375 BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED
  • TABLE 376 BIOSENSORS INTERNATIONAL GROUP, LTD: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 377 BIOTRONIK SE & CO. KG: COMPANY OVERVIEW
  • TABLE 378 BIOTRONIK SE & CO. KG: PRODUCTS OFFERED
  • TABLE 379 BIOTRONIK SE & CO. KG: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024

List of Figures

  • FIGURE 1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND OTHER PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 7 MARKET SIZE APPROACH - REVENUE SHARE ANALYSIS
  • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC (2023)
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 SUPPLY-SIDE ANALYSIS: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2023)
  • FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 CAGR PROJECTIONS
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 CATHETERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 OTHER DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 21 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 22 GEOGRAPHIC SNAPSHOT OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET
  • FIGURE 23 INCREASING PREVALENCE OF CVD AND DIABETES TO PROPEL MARKET
  • FIGURE 24 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2023
  • FIGURE 25 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 26 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 27 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 28 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 30 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 31 INDICATIVE AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023
  • FIGURE 32 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ECOSYSTEM MAP
  • FIGURE 33 PATENT PUBLICATION TRENDS (JANUARY 2013-OCTOBER 2024)
  • FIGURE 34 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR INTERVENTIONAL CARDIOLOGY DEVICES PATENTS (JANUARY 2013-OCTOBER 2024)
  • FIGURE 35 TOP APPLICANT COUNTRIES/REGIONS FOR INTERVENTIONAL CARDIOLOGY DEVICES PATENTS (JANUARY 2013-OCTOBER 2024)
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS
  • FIGURE 37 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 38 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET
  • FIGURE 39 INTERVENTIONAL CARDIOLOGY DEVICES: ADJACENT MARKETS
  • FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2019-2024
  • FIGURE 41 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC SNAPSHOT (2023)
  • FIGURE 42 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT
  • FIGURE 43 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT
  • FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2019-2023)
  • FIGURE 45 MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
  • FIGURE 46 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 47 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 48 INTERVENTIONAL CARDIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 49 EV/EBITDA OF KEY VENDORS
  • FIGURE 50 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 51 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 52 R&D ASSESSMENT OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2021-2023
  • FIGURE 53 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 54 MEDTRONIC: COMPANY SNAPSHOT (2023)
  • FIGURE 55 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 56 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 57 TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 58 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 59 B. BRAUN SE: COMPANY SNAPSHOT (2023)
  • FIGURE 60 INTEGER HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 61 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)
  • FIGURE 62 PENUMBRA, INC.: COMPANY SNAPSHOT (2023)